Clinical Trial Update: A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) [Phase 1, Phase 2]

View source ↗

Summary

GI Innovation's GI-102 is being studied in a phase 1/2 trial as a single agent and in combination with pembrolizumab or trastuzumab deruxtecan for various advan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Hepatocellular Carcinoma
• Platinum-resistant Ovarian Cancer
• Renal Cell Carcinoma
• Soft Tissue Sarcoma
• Solid Tumors

Drugs mentioned

• GI-102
• Pembrolizumab (pembrolizumab)
• Trastuzumab deruxtecan (trastuzumab deruxtecan)

Snippet

Sponsor: GI Innovation, Inc. | Conditions: Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1, Phase 2 | Status: RECRUITING